Should I Buy ACET? ACET 2026 Analysis

Should You Buy Adicet Bio Inc (ACET) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

7.030

1 Day change

9.16%

52 Week Range

17.440

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: the chart is still in a confirmed downtrend (bearish MA stack + weakening MACD), and there’s no near-term catalyst in the news flow.
A short-term oversold bounce is possible, but current price is already below S1 (7.786) with next support near S2 (7.465); downside risk to support is still present before a cleaner entry.
Options positioning is extremely call-skewed, but implied volatility is at extreme highs, signaling speculation and expensive optionality rather than “smart-money” conviction.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock today.

Technical Analysis

Trend: Bearish (SMA_200 > SMA_20 > SMA_5), indicating sustained downside pressure.
Momentum: MACD histogram -0.00968 and negatively expanding → bearish momentum is strengthening.
RSI: RSI_6 at 28.30 (near oversold) → bounce potential exists, but oversold alone is not a buy trigger in a strong downtrend.
Key levels: Pivot 8.306 (overhead), Resistance R1 8.825 then R2 9.146; Support S1 7.786 (already broken) with next support S2 7.465.
Price action context: Regular session -3.51% (risk-off tape with S&P 500 -0.85%) suggests ACET remains vulnerable when markets are weak.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Open interest put/call at 0.04 is extremely call-heavy (bullish tilt / speculative positioning).
Volatility: 30D IV ~885.64 with IV percentile 98.4 and IV rank 97.36 → options are priced for extreme moves; this often reflects uncertainty/speculation rather than stable bullish conviction.
Activity: Call volume 20 vs 30D average spike (today vs avg ~32.26) but absolute volume is still small; put volume is 0 → skewed but not deeply liquid confirmation.
Takeaway: Options market is “lottery-ticket bullish,” but the extreme IV makes directional bets expensive and can coincide with post-reverse-split volatility.

Technical Summary

Sell

Buy

Positive Catalysts

- Oversold setup (RSI near oversold) can support a reflex bounce if buyers defend the 7.46–7.50 area.
- Analyst stance remains Buy across recent notes, with targets recalibrated post reverse-split (supportive narrative on pipeline).
- Pattern-based projection provided: probabilistic drift higher over 1 week/1 month (+1.43% / +6.79%), suggesting potential rebound if support holds.

Neutral/Negative Catalysts

- Technical trend remains decisively bearish (bearish MA stack + deteriorating MACD), so rallies may be sold.
- No news in the last week → no clear event-driven catalyst to reverse trend quickly.
- Reverse split context (to maintain listing) often coincides with elevated volatility and weaker sentiment.
- Extremely high implied volatility suggests uncertainty and can coincide with sharp drawdowns.
- Institutional/insider flows: hedge funds neutral; insiders neutral → no strong accumulation signal.
- Politicians/congress: no recent congress trading data available (no influential-flow confirmation).

Financial Performance

Latest quarter: 2025/Q3.
Revenue: effectively 0 (pre-revenue profile).
Profitability: Net income -$26.86M (worsened ~11.88% YoY); EPS -4.72 (worsened ~12.10% YoY) → losses expanding, typical of clinical-stage biotech but still a headwind without catalysts.
Growth trend takeaway: operating performance is not improving yet; price action will likely be driven by pipeline milestones/financing expectations rather than fundamentals.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Overall trend: analysts maintained Buy ratings while price targets were mechanically adjusted around the 1-for-16 reverse split (big nominal target changes largely reflect share-count changes).
2026-01-21: H.C. Wainwright raised PT to $50 from $9 (kept Buy), citing reverse split adjustment.
2026-01-06: Canaccord lowered PT to $18 from $128 (kept Buy), explicitly adjusting for reverse split.
2025-11-07: H.C. Wainwright raised PT to $9 from $4 (kept Buy), citing attractive ADI-001 profile.
Wall Street pros vs cons: Pros = supportive pipeline narrative and consistent Buy ratings; Cons = targets are heavily split-adjustment-driven and not accompanied by fresh near-term catalysts or improving financial trajectory.

4 Analyst Rating

Wall Street analysts forecast ACET stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACET is 10.67 USD with a low forecast of 5 USD and a high forecast of 18 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 6.440

Low

Averages

10.67

High

Current: 6.440

Low

Averages

10.67

High

H.C. Wainwright

NULL -> Buy

upgrade

$9 -> $50

AI Analysis

2026-01-21

Reason

H.C. Wainwright

Price Target

$9 -> $50

AI Analysis

2026-01-21

upgrade

NULL -> Buy

Reason

H.C. Wainwright raised the firm's price target on Adicet Bio to $50 from $9 and keeps a Buy rating on the shares. The firm cites the recent reverse stock split for the target change.

Canaccord

Buy

downgrade

$128 -> $18

2026-01-06

Reason

Canaccord

Price Target

$128 -> $18

2026-01-06

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Adicet Bio to $18 from $128 and keeps a Buy rating on the shares. The firm adjusted its price target to reflect a one-for 16 reverse stock split that took effect on December 30, 2025, to maintain listing requirements on the NASDAQ. This reverse split results in a total of approximately 9.6 million shares of common stock outstanding.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ACET

Unlock Now

ACET Should I Buy

ACET Should I Buy

Should You Buy Adicet Bio Inc (ACET) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch